Accolade (ACCD) Stock Price, News & Analysis

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings or view top-rated stocks.

16 Wall Street analysts have issued 1 year target prices for Accolade's stock. Their ACCD share price targets range from $12.00 to $19.00. On average, they anticipate the company's stock price to reach $15.67 in the next year. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts.

Accolade's stock was trading at $12.01 on January 1st, 2024. Since then, ACCD shares have decreased by 27.6% and is now trading at $8.70.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ACCD earnings forecast.

Accolade will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Accolade, Inc. (NASDAQ:ACCD) issued its quarterly earnings results on Thursday, April, 27th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.01. The firm had revenue of $99.03 million for the quarter, compared to the consensus estimate of $99.44 million. Accolade had a negative trailing twelve-month return on equity of 27.27% and a negative net margin of 31.59%. Accolade's revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.59) earnings per share.

ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

Accolade (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Accolade's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.07%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes.
View institutional ownership trends.

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.